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Purpose: This report describes the results of  a phase 1 trial of  endovascular repair o f  
abdominal aortic aneurysm, conducted under FDA protocol in 13 U.S. medical centers 
from February 1993 to December 1994. 
Methods: Forty-six patients 54 to 84 years of  age underwent endovascular repair of  
abdominal aortic aneurysm (diameter, 3.8 to 7.1 cm). Fifteen were treated with the 
original device (EGS-I),  and 31 with a revised over-the-wire system (EGS-I I) .  All patients 
were periodically observed with contrast-enhanced computed tomographic scan, color- 
flow duplex scan, and plain abdominal  films to evaluate the stability of  prosthetic location 
and to detect any vascular communication with or entry of  blood into the aneurysm sac or 
change in aneurysm size. 
Results: Thirty-nine implants (85%) were successful; average operating time was 194 
minutes. Seven attempts were unsuccessful and were converted to open repair without 
complication (EGS-I,  5 of  15; EGS- I I ,  2 of  31). Conversions were caused by iliac stenosis 
in four patients, subintimal deployment in one, proximal displacement in one, and short 
distal neck in one. No patients died within 30 days of  surgery. Complications included 
myocardial infarction in one patient, il iofemoral arterial injury in eight, wound infection 
in seven, required transfusion in eight, transient unexplained fever in nine, and minor 
emboli with foot petechiae in two. There were no amputations, major emboli, or episodes 
of  mesenteric schemia. Contrast enhancement outside the graft but within the aneurysm 
sac was detected initially in 17 grafts (44%), of  which nine (53%) resolved spontaneously. 
Of  eight persistent leaks into the aneurysm sac, one was control led with transluminal 
balloon angioplasty and one required surgical explantation because of  aneurysm enlarge- 
ment. Six patients continued to have contrast enhancement, but had no evidence of  
aneurysm enlargement from 6 to 27 months after surgery. Hospital  stay averaged 3.8 days 
(range, I to 13 days). Fol low-up extends to 27 months, with one non-device related eath 
of  respiratory failure at 6 months. Metallic attachment system fracture, a device-related 
malfunction, was identified in nine implants (23%), which led to one removal; the 
remaining eight functioned normally with no untoward sequelae. The program was 
suspended while the defect was corrected. Preparations are complete for the phase 2 
port ion of  the trial. 
Conclusions: Endovascular repair of  abdominal aortic aneurysm appears to be safe and 
efficacious. Long-term results and late consequences of  attachment system fracture have yet 
to be determined. The long-term results of  perigraft leak into the aneurysm sac are 
unknown but worrisome in view of  adverse outcomes reported by other investigators. 
(J VAsc SURG 1996;23:543-53.) 
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Experimental studies of  endovascular grafting 
date back to 1969.1 The first clinical experience with 
the endovascular repair o f  abdominal  aortic aneurysm 
(AAA), however, was reported by Parodi and col- 
leagues in 1991.2 Reports since have been publ ished 
of  other endovascutar repair o f  AAA with hand- 
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assembled devices made from components hat were 
designed for other purposes. 3-s The first device that 
was specifically manufactured for the endovascular 
repair of AAA was designed by Harrison M. Lazarus 
and was developed by Endovascular Technologies, 
Inc. (Menlo Park, Calif.). 6'7 To date, this is the only 
device to receive Food and Drug Administration 
(FDA) approval for clinical trial in the United States. 
The first implant of this device was performed at the 
University of California Los Angeles (UCLA) Medi- 
cal Center on February 10, 1993; the initial experi- 
ence with the device at that institution was subse- 
quently reported, s-ll The objective of this report is to 
describe the complete multiinstitutional experience of 
an FDA-approved phase i trial for transfemoral repair 
of AAA with the endovascular g afting system (EGS). 
STUDY DESIGN 
The FDA-approved study design will occur in 
three phases. Phase 1 was designed to test the safety 
and efficacy of a limited number of implants in 
patients with AAA. Initially, three phase 1 centers 
were selected: Stanford University, the University of 
California San Francisco, and UCLA. In preparation 
for phase 2 an additional 10 centers were added, 
bringing the total to 13. The institutions and inves- 
tigators are listed in the Appendix. Phase 2 is a 
prospective comparison of the results oftransfemoral 
endograft placement versus those of conventional 
transabdominal AAA repair. Phase 3 is designed to 
look at the long-term results of endovascular repair 
with respect o stability and durability of the device 
and ability to protect against aneurysm enlargement 
and rupture. 
MATERIALS AND METHODS 
Patient screening. The EGS system was designed 
to be used in patients who have AAAs that can be 
repaired with a tubular graft. Therefore there must be 
an adequate neck (1.5 to 2.0 cm) between the lower 
renal artery and the beginning of the aneurysm, and 
a sufficient length of aorta (1.5 to 2.0 cm) between 
the distal portion of the aneurysm and the aortic 
bifurcation. The patients' general medical condition 
must be satisfactory for general anesthesia and accept- 
able for conventional repair of thcir AAA should 
conversion from endovascular repair to conventional 
repair be required. Inclusion criteria are summarized 
in Table I; exclusion criteria re summarized in Table 
II. 
When patients were identified as having AAAd and 
were referred for possible inclusion in the trial, they 
underwent several imaging procedures to be certain 
that they conformed with the anatomic inclusion and 
exclusion criteria. First, a contrast-enhanced com- 
puted tomographic (CT) scan with 3.0-ram cuts was 
obtained. This scan permitted accurate measurement 
of the diameter of segments of uninvolved aorta 
proximal and distal to the aneurysm. The diameter of 
the aneurysm could not exceed 28.0 mm, which was 
the largest graft diameter available during the study. 
The diameter of the AAA also was measured. If these 
measurement criteria were met, the patient was sched- 
uled for an abdominal ngiogram. The angiogram was 
performed with a marker catheter to permit accurate 
intraluminal measurement with correction for mag- 
nification factor. The angiogram provided informa- 
tion concerning tortuosity, evidence of collateral 
mesenteric flow pattern, aberrant renal artery 
anatomy, and an accurate measurement of the length 
of the graft required. The length from the point of 
proposed placement of the proximal attachment sys- 
tem (below the lowest renal artery) to the distal neck 
of the aorta (proximal to the aortic bifurcation) could 
not exceed 13.0 cm, which was the longest available 
graft length. When patients passed these two screen- 
ing imaging procedures and were determined tohave 
no exclusion factors, they were considered candidates 
for endovascular repair. Informed consent hen was 
obtained. 
Device and technique of  implantation. The 
EGS is composed of two main components: the 
EndoGraft endovascular p osthesis (Fig. 1) and the 
endovascular deployment assembly (Fig. 2). Also 
included is the EVT expandable introducer sheath, 
which is used to cannulate the vascular system and 
serves as an operating channel for angiography, device 
introduction, and deployment (Fig. 3). The device 
underwent several modifications during the early 
course of the phase 1 trial. The initial endovascular 
deployment assembly had a self-seeking uidewire 
intrinsic to the device. The subsequent assembly 
(EGS-II), which is an over-the-wire system, was used 
in most of the phase 1 trial. 
The patients who had been evaluated and deemed 
candidates for endovascular repair were brought o 
the operating room and were given general anesthe- 
sia. The patient's abdomen and groin on both sides 
were prepared and outlined with sterile drapes. One 
femoral artery was surgically exposed through a 
vertical incision. The common femoral artery was 
mobilized from the inguinal igament to the femoral 
bifurcation. If evidence of tortuosity of the external 
iliac artery was present or if additional length of vessel 
appeared to be required, the medial and lateral 
circumflex branches were divided and the leading 
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Table I. Inclusion criteria 
21 years of age or older 
Male or infertile female patients 
Infrarenal AAA with at least 2.0 cm superior and inferior 
cuffs of nonaneurysmal vessel 
Anesthesia clearance (class I, II, or III) 
Patient lives within 100 miles of institution (available for 
follow-up) 
Informed consent signed 
At least one femoral-iliac rtery without limiting occlu- 
sion or ectasia 
Femoral artery can accommodate  23F device (7.7 mm) 
edge of the inguinal ligament incised to permit 
mobilization or straightening of the external iliac 
artery to provide more linear access to the common 
iliac artery. 
After the femoral artery was exposed, it was 
punctured with a 9F angiography sheath, which was 
then advanced over a guidewire. A marker angiogra- 
phy catheter and an Amplatz J-tipped guidewire were 
then inserted into the sheath and advanced under 
fluoroscopic ontrol up to the suprarenal aorta (Fig. 
4). The guidewire then was removed, and an aorto- 
gram with a pressure injector was obtained and 
recorded on the fluoroscopy screen with road-map- 
ping technology. This image served as a guide for 
subsequent technical maneuvers. The use of a marker 
catheter provided one additional opportunity to mea- 
sure anatomic dimensions and to assure that the 
appropriate length of graft had been selected. The 
catheter has radiopaque marks at 1-cm intervals, and 
accurately measures the distance between the point of  
proposed placement of the proximal attachment sys- 
tem (below the renal arteries) and the point of 
proposed placement of the distal attachment system 
(within the distal neck of the aneurysm proximal to  
the aortic bifurcation). The patient was placed on a 
radiolucent marker board with movable transverse 
radiopaque cursor lines, which were then adjusted to 
mark the levels chosen for proximal and distal graft 
deployment. 
The patients were given 5000 IU intravenous 
heparin. With the guidewire left in place, the angiog- 
raphy catheter and the angiogram sheath were re- 
moved. The femoral artery was clamped proximal and 
distal to the puncture site where the guidewire 
emerged. The puncture site was then enlarged to 
create atransverse arteriotomy. The EVT expandable 
sheath was introduced over the guidewire and ad- 
vanced into the arteriotomy. Using digital control of 
the proximal femoral artery for hemostasis, the proxi- 
mal clamp was removed and the sheath was advanced 
over the guidewire, under fluoroscopic ontrol, up 
Table I I .  Exclusion criteria 
Aneurysm neck diameter >28 mm 
Ruptured AAA 
Infection 
Underlying disease limiting expected survival to <2 years 
Weight >2• Metropolitan Life Table normal value 
Currently being treated with another investigational drug 
or device 
Significant iliac or femoral occlusive disease 
Significant lilac artery ectasia/aneurysm 
Noniatrogenic bleeding diathesis 
Connective tissue disease (e.g., Marfan's yndrome) 
Previous left colectomy or sigmoid colectomy 
Angiographic evidence of meandering mesenteric artery 
the iliac segment and well into the aneurysm. The 
dilator housed within the sheath was advanced to fully 
expand the distal end of the sheath, and was left in 
place for 1 minute to allow the sheath to be fully 
expanded and set at body temperature. The dilator 
then was removed, and hemostasis within the sheath 
was controlled by a two-valve system: a proximal 
spring valve and a distal thumb-wheel valve. 
The endovascular deployment assembly then was 
prepared for insertion into the sheath. In  the earlier 
version, the guidewire was removed from the sheath, 
and the endovascular deployment assembly, with an 
intrinsic self-seeking uidewire, was inserted. With 
the later version (EGS-II), the assembly was loaded 
over the guidewire and advanced up the sheath to the 
aortic position. This part of the procedure was done 
entirely under fluoroscopic ontrol, using as guides 
the radiopaque markers, the road-mapped image, and 
the cursor lines of the marker board. The introducer 
sheath, which initially was advanced into the aorta, 
was backed into the iliac artery, which permitted the 
endovascular p osthesis portion of the assembly to be 
positioned within the aneurysm. The proximal attach- 
ment system was positioned just below the renal 
arteries, and the distal attachment system was posi- 
tioned well within the distal neck but proximal to the 
bifurcation of the abdominal aorta. 
The outer jacket that covers the prosthesis was 
then partially retracted in preparation for placement 
of the superior attachment system. The superior 
capsule was advanced, which allowed the superior 
attachment system to spring open and engage the 
proximal neck of the abdominal aorta above the 
aneurysm and below the renal arteries. The coaxial 
balloon was advanced into position and spanned the 
proximal attachment system. The balloon was inflated 
to 2 atmospheres todrive the pins that are part of  the 
attachment system into the wall of the aorta (Fig. 5). 
The balloon was held in place for 1 minute, then 
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Fig. 1. A, Opened-out appearance of endograft, a lightweight woven-Dacron graft. Radio- 
paque markers have been sewn in longitudinal xis. Both proximal and distal attachment systems 
are fully expanded. B, End-on view ofendograft. Attachment system isfully expanded; six radially 
arranged pins are designed to engage wall of aorta and are seated with expandable balloon. 
Fig. 2. A, Components ofendovascular deployment system. At top is handle of EGS-II device 
with various control knobs visible. At middle is distal end of catheter delivery system with capsule 
containing raft. At bottom is expanded prosthesis. B, Enlarged version of distal end of catheter 
delivery system shows graft compressed within capsule and covered with clear jacket. 
deflated, rotated, and reinflated for 1 more minute. 
During the deflation phase, blood entered the graft 
and caused it to fully expand down to the inferior 
capsule. The balloon was reinflated and adjustments 
were made to assure proper positioning. The balloon 
was deflated and the inferior capsule was retracted, 
which permitted the inferior attachment system to 
spring open and engage the distal neck of  the AAA 
proximal to the aortic bifurcation. The balloon then 
was positioned to bridge across the distal attachment 
system and inflated and deflated twice to seat the 
distal attachment system in the distal neck. The 
balloon then was deflated, permitting blood flow to 
the iliac arteries. The marker angiogram catheter 
then was reinserted over the guidewire into the 
suprarenal aorta, and a completion angiogram was 
obtained to establish the functioning of the graft, to 
determine the completeness of seal between the 
attachment systems and the aorta, and to detect any 
perigraft leak into the aneurysm (Fig. 6). The ex- 
pandable sheath and guidewire were removed, and 
the arteriotomy was sutured. The femoral incision 
site was closed, and the patients then were returned 
to the recovery room. When patients awakened from 
general anesthesia, they were taken to a regular 
hospital room. Intensive care monitoring usually was 
not required. Patients were discharged from the 
hospital as early as the next morning. 
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Fig. 3. A, Overall view of EVT expandable sheath. Distal end of sheath is collapsed, and 
obturator, in position, has not yet been advanced. B, Proximal portion of EVT expandable 
sheath. Note that gate vane is closed and in hemostatic position. 
Follow-up protocol. Before hospital discharge, 
each patient underwent a repeat contrast-enhanced 
CT scan to image the graft and to determine whether 
any contrast enhancement of the aneurysm sac was 
present. Contrast enhancement within the aneurysm 
sac may signify either an incomplete seal of the 
proximal or distal attachment systems or backbleed- 
ing from an inferior mesenteric or lumbar artery into 
the aneurysm sac. Additional imaging procedures 
were obtained, including plain films of the abdomen 
to identify the positions of the radiopaque proximal 
and distal attachment systems and the longitudinal 
radiopaque markers along the lateral aspects of the 
graft. Finally, color-flow duplex scanning of the ab- 
dominal aorta was performed to serve as an additional 
confirmation of flow through the graft and the 
absence of flow within the aneurysm. Ultrasonogra- 
phy and abdominal plane film imaging were repeated 
6 weeks, 6 months, and 1 year after implantation. 
Contrast-enhanced CT scans were performed at 6 
months, 1 year, and annually thereafter. More fre- 
quent imaging was performed as required. 
Extensive reporting forms for the FDA are main- 
tained by each hospital that describe the details of the 
patient's history, physical findings, laboratory data, 
imaging studies, implant information, morbidity, 
mortality, and details of follow-up assessment. Any 
late complications or explant information are also 
carefully recorded. 
RESULTS 
From February 10, 1993, to December 6, 1994, 
46 patients underwent endovascular.repair of an AAA 
with the EGS system. The repairs took place in 13 
centers (Appendix). The number of implants per- 
formed at each center varied from 1 to 13. 
The patients' ages ranged from 54 to 84 years with 
a mean of 71.6 years. Forty-one were men; five were 
women. Fifteen implants were performed with the 
original EGS system and 31 with the EGS-II device. 
Patient comorbid factors are summarized inTable III. 
Aorta and aneurysm easurements are summarized 
in Table IV. 
The diameter of the grafts ranged from 18.0 to 
28.0 mm. The most common diameter was 24.0 mm, 
which was used in 26 patients. Graft length varied 
from 8.5 to 13.0 cm. Twenty-nine patients had graft 
lengths ranging from 9.0 to 10.5 cm. The duration of 
surgery from skin incision to closure averaged 194 
minutes (range, 106 to 322 minutes). 
30-day morbidity and mortality rates. None of 
the 46 patients died within 30 days of undergoing 
the procedure. Complications are summarized in 
Table V. One patient had a mild myocardial infarction 
after surgery. No instances of major thromboembo- 
lism or mesenteric schemia occurred. Two patients 
had minor thromboembolic episodes manifested by 
minimal petechiae; both resolved spontaneously. 
Eight patients (17%) each required one blood trans- 
fusion for bleeding associated with device insertion, 
usually through the expandable sheath. Six patients 
experienced superficial cellulitis of the femoral inci- 
sion that responded to conservative measures, one 
patient experienced lymphorrhea that required ebri- 
dement, and nine patients had postoperative f ver of 
unknown cause that resolved spontaneously. Seven 
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Fig. 4. Artist's rendering of marker catheter in position, 
having been passed over guidewire through 9F angiography 
sheath. 
patients required conversion to conventional trans- 
abdominal repair. Six of these conversions were im- 
mediate and were related to problems with graft 
positioning, insertion, or placement. One patient 
required conversion to conventional repair on the 
fourth day after surgery because of subthrombot- 
ic/intimal positioning of the device within the an- 
eurysm sac. Eight iliotizmoral arterial injuries oc- 
curred. Four were minor and required only local 
femoral artery repair coincident with arteriotomy 
closure. Three required iliofemoral or fizmoroti:mo- 
ral bypass, and one required aortobifcmoral bypass 
as a part of the conversion to open repair. Only one 
patient had mild, temporary renal dysfunction, 
which resolved spontaneously without dialysis. 
Hospital ization data. Only eight of the 39 
patients who underwent successful cndovascular 
grafting required a stay in an intensive care unit. The 
average total hospital stay from surgery to discharge 
was 3.8 days (range, 1 to 13 days). Twenty-eight 
patients (72%) were discharged within 3 days. 
Fol low-up status. The series began on February 
10, 1993, and reported follow-up is complete to May 
1, 1995. The three patients who were observed the 
longest in the series were alive and well at 27 months, 
24 months, and 22 months after implantation. In an 
aggregate of 544 follow-up months in the 39 patients, 
the implants have all functioned successfully. The 
mean duration of follow-up is 14 months. One patient 
died of respiratory failure 6 months after implanta- 
tion. No late aneurysm rupture has occurred. 
Contrast enhancement o f aneurysm sac. Con- 
trast-enhanced CT scan showed that 17 of 39 patients 
(44%) had flowing blood in the aneurysm sac imme- 
diately after implantation. This information and that 
from color-flow duplex scanning identified the proxi- 
mal fixation site as the point of leak in five patients, the 
distal fixation site in ten, and an unknown site in two. 
The unknown sites most likely represent backbleed- 
ing from either lumbar arteries or an inferior mesen- 
teric artery. During the course of  follow-up, nine of 
the 17 leaks closed spontaneously. Two were closed by 
the time of hospital discharge, three within 6 weeks, 
three between 6 weeks and 6 months, and one 
spontaneously closed after 6 months. 
Of  the eight patients with persistent leaks, five 
underwent an attempt at repeat percutaneous trans- 
luminal balloon angioplasty, which was successful in 
one patient. Two other leaks met with initial success 
but subsequently reopened. Two were overt failures, 
one leading to late surgical explantation and conver- 
sion to open repair. Thus, six patients continue to have 
contrast enhancement of the aneurysm sac. All six 
patients are well and without evidence of enlargement 
of the aneurysm sac. These patients continue to be 
observed carefully with frequently repeated physical 
examination and CT scanning. 
Conversion to open repair. Six patients required 
immediate conversion to open repair after unsuccess- 
ful endovascular g afting. The reasons for conversion 
included accumulation of atherosclerotic plaque in 
the iliac artery, which prevented sheath insertion in 
three patients; inability to dilate the sheath in one; 
failure of the attachment system hooks to penetrate 
the plaque in the proximal neck in one; and an 
inadequate l ngth of distal neck in one. One conver- 
sion occurred 4 days after surgery as a result of 
misplacement of the graft between aneurysm wall and 
mural thrombus. In addition, two late conversions to 
open repair were performed. One graft, mentioned 
earlier, was converted to open repair after unsuccess- 
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ful reseating of the attachmcnt system by pcrcutanc- 
ous balloon angioplasty in a patient with documented 
increase in aneurysm diameter during observation. 
The second patient who required conversion to an 
open repair had a fracture of the proximal attachment 
system with distal migration during the course of 
observation. The fracture was first noticed in retro- 
spect on the plain films taken at 6 months, and the 
dcvicc migration became apparent at 16 months, 
which led to its removal 17 months after implanta 
tion. No evidence of leak or aneurysm enlargement 
was fbund. 
Attachment system fracture. One patient, al- 
ready mentioned as having a persistent leak associated 
with the distal attachment system and aneurysm 
enlargement 12 months after implantation, under- 
went surgical removal and conversion after an unsuc- 
cessful attempt o repeat balloon angioplasty of the 
distal attachment system. When explantation was 
performed, one pin each on the proximal and distal 
attachment systems was fractured. This led to a 
retrospective r view of all plain films in all patients. 
During the review and subsequent observation, frac- 
tures developed in one or more of  the metal compo- 
nents of the attachment system in nine patients. This 
problem was reported to the FDA immediately on 
recognition, and the implant program was suspended 
while the causes and the consequences of this com- 
plication were examined. During follow-up, eight of 
the nine patients with fractures in the attachment 
system continued to be observed with no evidence of 
adverse sequelae. Only the one patient described 
above underwent explantation and conversion to 
open repair 18 months after initial implantation. 
Identification of the attachment system fracture 
was subtle, and often required the use of 2.5-power 
loupe magnification and requests tbr additional ob- 
lique views of abdominal plane films for attachment 
system fractures to be identified. Initially none of 
these fractures were seen or reported by the individual 
institution radiologists. The problem was only iden- 
tified at the time of the above-mentioned xplant. Of 
the nine patients with attachment system fracture, 
seven were seen at the 6-month abdominal plane film 
examination, and two were seen at 12 months. The 
mean interval between implantation and the identifi- 
cation of attachment system fracture was 7.3 months. 
Of  the eight patients with documented attachment 
system fracture who are currently being observed, the 
interval between attachment system fracture and the 
Fig. 5. Ex-vivo demonstration f placement of proximal 
attachment system. Jacket has been retracted and proximal 
capsule xpanded to permit proximal attachment system to 
deploy. Balloon catheter has been advanced to bridge across 
proximal attachment system and is now fully inflated, which 
serves to drive radial pins into wall of aorta. 
time of  this publication ranges fi~om 10 to 20 months 
with a mean of 14 months. 
D ISCUSSION 
Since the introduction of direct repair of AAA by 
Dubost ct al, ~2 the surgical repair of AAA has bccn 
one of  the most important and successful chapters 
in vascular surgery. For the first time, a definitive cure 
of this otherwise fatal disease was established. With 
thc increasing frcqucncy of this procedure, the care- 
ful training of vascular surgeons, and technical im- 
provements, thc morbidity and mortality ratcs of 
ancurysm repair have steadily dcclincd over the years. 
Currently, centers of excellence report mortality 
rates <3.0% for clcctivc repair) 3 Despite this figure, 
community-based reports suggest that the overall 
experience with direct repair of AAA continues to 
carry a mortality rate of approximately 10%. 14 If 
transtEmoral cndovascular repair of  AAA is shown to 
be durable in the long term, it will have a major 
impact on the 30-day mortality rates ofpaticnts who 
undcrgo ancurysm repair. In this initial phase 1 
experience no patients died within 30 days of sur- 
gery. Clearly, the opportunity to place a graft in the 
infrarenal abdominal aorta through a femoral arte- 
riotomy, despitc the risks of general anesthesia, will 
have a major impact in improving the safety of 
aneurysm repair and may also have an impact on the 
size of  aneurysms that will be considered candidates 
fbr repair. Currently the lower size limit in most 
series is approximately 5.0 cm. It is generally believed 
that open surgery for aneurysms <5.0 cm are not 
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Fig. 6. A, After deployment ofprosthesis, completion angiogram is obtained to demonstrate all 
aortic flow through graft. No evidence of perigraft leak into aneurysm sac was detected. B, 
Angiogram shows perigraft leak into aneurysm sac from proximal anastomosis. 
Table III. Comorbid factors 
No. of patients % 
Smoking history 37 80 
Hypertension 25 54 
Coronary artery disease 14 30.4 
Chronic obstructive pulmonary disease 6 13 
Peripheral vascular disease 3 6 
Previous troke 3 6 
Diabetes 2 4 
Renal dysfunction 1 2 
beneficial because of an adverse risk/benefit ratio 
considering current mortality rates. If  this operation 
can be performed with minimal morbidity and mor- 
tality rates, operations on smaller aneurysms may 
well be considered appropriate, particularly because 
the small aneurysm ay represent a better anatomic 
situation for endovascular g afting. Thus allowing an 
aneurysm to enlarge may remove the option of 
endovascular repair and commit he patient o direct 
open surgical repair. 
Patients who undergo repair of an AAA are 
normally committed to a hospital stay of 7 days or 
longer if complications occur. Successful transfemoral 
repair of AAA should require little more than a 
24-hour stay, and may ultimately reach the point 
where the procedure can be done in an outpatient 
surgery center. Intensive care monitoring normally is 
not required, and there is no postoperative ileus. 
Therefore, after implantation and recovery from an- 
esthesia the patient can be up and about and begin to 
take oral alimentation, obviating the need for intra- 
venous fluid management. Finally, as experience is
gained with this technique and the surgeon becomes 
more facile with device insertion, catheter changes, 
and control of backbleeding from the sheath, the 
surgery could be done in 1 hour without ransfusion. 
All of these improvements may translate to a great 
reduction in the cost associated with treatment of 
AAA. 
Most patients with AAA are not candidates for 
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Table IV. Aorta and aneurysm easurements 
Range (mm) Mean (mm) 
Proximal neck length 13.5 to 48 24.8 
Distal neck (cuff) length 10 to 45 15.7 
Aneurysm A-P diameter 38 to 71 52.0 
Table V. Postoperative (30-day) complications 
No. % 
Conversion to open repair 7 l 5 
Myocardial infhrction I 2 
Iliofemoral arterial injury 8 17 
Minor thrombocmbolism 2 4 
Superficial cellulitis 6 13 
Lymphatic leak 1 2 
Postoperative f ver 9 20 
endovascular tube graft repair. Although screening 
statistics were not a requirement of the study, one 
study center did maintain these data; they reported 
that it was necessary to screen 69 patients to identify 
the 10 who subsequently received tube graft repair. 
The most common cause of rejection was the lack of 
a distal neck. sThis limitation ow is addressed by the 
availability of endovascular bifurcated prostheses. 
When a patient is identified who is a candidate for tube 
graft repair, however, aconsiderable advantage li s in 
using a tube prosthesis rather than a bifurcation graft, 
particularly from tfic perspective of the simplicity of 
insertion and the relative brevity of operating time. 
The literature now contains a number of reports 
that describe various devices for the endovascular 
repair of AA-A-. 3-s Although these techniques are 
innovative and may contribute to this new technol- 
ogy, the reports are retrospcctive, uncontrolled, and 
often missing essential details. The EGS system was 
designed and manufactured specifically for endovas- 
cular repair of AAA; it was not assembled from 
components designed for other uses. In addition, it 
has received ctailed review and approval by the FDA 
for experimental implantation in carefully selected 
and controlled centers. Every detail of patient selec- 
tion, implantation, and fi)llow-up are carefully re- 
corded on protocols approved and reviewed by the 
FDA. This review assures protection of the patient 
population and the public at large during the evalua- 
tion of an unprovcn experimental device. An example 
of the benefit of these strict criteria occurred with the 
discovery of attachment system fracture. This identi- 
fication required and resulted in an immediate report 
to the FI)A, and the placement of any fiirther implants 
was delayed until the problem could be rectified and 
the long-term implications studicd. Although the use 
of a strict protocol is possible in a non-FDA-regulated 
environment, it is unlikely that the problem would 
have been idcntified and reported as rapidly it was in 
this circumstance. The mechanical problem has been 
identified and corrected. The redesigned attachment 
systems have been extensively tested and the resuhs 
reviewed by the FDA. FDA approval has now been 
received to resume phase 2 of the implant study. 
CONCLUSION 
The results of phase 1 have clearly demonstrated 
that endovascular repair of AAA is both safe and 
effective in the short term. Most conversions oc- 
curred early in the series, and primarily with the initial 
EGS design. As more experience was gained, only two 
of the final 31 implants with EGS-II required conver- 
sion. A potential major problem, that of attachment 
system fracture in some patients, has been identified 
and corrected. Only one patient required explanta- 
tion because of graft migration associated with proxi- 
mal attachment system fracture. The remaining eight 
patients have good, functioning rafts without evb 
dence of migration and will be carefully observed. 
Future models for implantation will undoubtedly 
have more durable attachment systems and will likely 
be free of subsequent mechanical problem. 
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